Robert B Sim

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3762867/publications.pdf

Version: 2024-02-01

298 papers	20,978 citations	7568 77 h-index	11939 134 g-index
326 all docs	326 docs citations	326 times ranked	16543 citing authors

#	Article	IF	Citations
1	Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients.. Proceedings of the National Academy of Sciences of the United States of America, 1987, 84, 8628-8632.	7.1	1,270
2	The Impact of Glycosylation on the Biological Function and Structure of Human Immunoglobulins. Annual Review of Immunology, 2007, 25, 21-50.	21.8	1,180
3	Glycosylation changes of IgG associated with rheumatooid arthritis can activate complement via the mannose-binding protein. Nature Medicine, 1995, 1, 237-243.	30.7	729
4	Collectins: collagenous C-type lectins of the innate immune defense system. Trends in Immunology, 1994, 15, 67-74.	7.5	462
5	Complement activation and protein adsorption by carbon nanotubes. Molecular Immunology, 2006, 43, 193-201.	2.2	395
6	C1q and tumor necrosis factor superfamily: modularity and versatility. Trends in Immunology, 2004, 25, 551-561.	6.8	392
7	Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases. Nature Immunology, 2005, 6, 920-927.	14.5	363
8	Macrophage complement and lectin-like receptors bind Leishmania in the absence of serum.. Journal of Experimental Medicine, 1985, 162, 324-331.	8.5	309
9	Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature, 2009, 458, 890-893.	27.8	287
10	Human leukocyte C1q receptor binds other soluble proteins with collagen domains.. Journal of Experimental Medicine, 1990, 172, 955-959.	8.5	279
11	Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. Journal of Immunological Methods, 2005, 296, 187-198.	1.4	270
12	Filled and glycosylated carbon nanotubes for in vivo radioemitter localization and imaging. Nature Materials, 2010, 9, 485-490.	27.5	267
13	Three-dimensional structure of a complement control protein module in solution. Journal of Molecular Biology, 1991, 219, 717-725.	4.2	240
14	Complement system proteins which interact with C3b or C4b A superfamily of structurally related proteins. Trends in Immunology, 1986, 7, 230-234.	7.5	232
15	Simultaneous Activation of Complement and Coagulation by MBL-Associated Serine Protease 2. PLoS ONE, 2007, 2, e623.	2.5	220
16	Functional Significance of Factor H Binding toNeisseria meningitidis. Journal of Immunology, 2006, 176, 7566-7575.	0.8	219
17	Solution Structure of a Pair of Complement Modules by Nuclear Magnetic Resonance. Journal of Molecular Biology, 1993, 232, 268-284.	4.2	211
18	Human Serum IgM Glycosylation. Journal of Biological Chemistry, 2005, 280, 29080-29087.	3.4	209

#	Article	IF	Citations
19	Local opsonization by secreted macrophage complement components. Role of receptors for complement in uptake of zymosan.. Journal of Experimental Medicine, 1984, 159, 244-260.	8.5	208
20	Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 7544-7549.	7.1	207
21	Natural Substrates and Inhibitors of Mannan-Binding Lectin-Associated Serine Protease-1 and -2: A Study on Recombinant Catalytic Fragments. Journal of Immunology, 2003, 170, 1374-1382.	0.8	202
22	Disease-associated Mutations in Human Mannose-binding Lectin Compromise Oligomerization and Activity of the Final Protein. Journal of Biological Chemistry, 2004, 279, 21302-21311.	3.4	198
23	Complement in health and disease. Advanced Drug Delivery Reviews, 2011, 63, 965-975.	13.7	189
24	An IgG autoantibody which inactivates C1Â¯-inhibitor. Nature, 1986, 323, 722-724.	27.8	184
25	Distinct Pathways of Mannan-Binding Lectin (MBL)- and C1-Complex Autoactivation Revealed by Reconstitution of MBL with Recombinant MBL-Associated Serine Protease-2. Journal of Immunology, 2000, 165, 2093-2100.	0.8	184
26	Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood, 2009, 113, 1909-1918.	1.4	183
27	Structure, Organization, and Regulation of the Complement Genes. Annual Review of Immunology, 1988, 6, 161-195.	21.8	176
28	C1q and its growing family. Immunobiology, 2007, 212, 253-266.	1.9	174
29	Structural basis for complement factor Hâ€“linked age-related macular degeneration. Journal of Experimental Medicine, 2007, 204, 2277-2283.	8.5	168
30	Proteases of the complement system. Biochemical Society Transactions, 2004, 32, 21-27.	3.4	163
31	The functions and relationships of Ty-VLP proteins in yeast reflect those of mammalian retroviral proteins. Cell, 1987, 49, 111-119.	28.9	162
32	His-384 Allotypic Variant of Factor H Associated with Age-related Macular Degeneration Has Different Heparin Binding Properties from the Non-disease-associated Form. Journal of Biological Chemistry, 2006, 281, 24713-24720.	3.4	161
33	Impaired Binding of the Age-related Macular Degeneration-associated Complement Factor H 402H Allotype to Bruch's Membrane in Human Retina. Journal of Biological Chemistry, 2010, 285, 30192-30202.	3.4	159
34	Glycosylation and the Complement System. Chemical Reviews, 2002, 102, 305-320.	47.7	155
35	The human IL-1 receptor antagonist gene (IL1RN) maps to chromosome 2q14â€“q21, in the region of the IL-1Î± and IL-1Î² loci. Genomics, 1992, 13, 654-657.	2.9	154
36	Differential elution of Clq, ClÌ„r and ClÌ„s from human CT bound to immune aggregates. use in the rapid purification of ClÌ„ sub-components. Molecular Immunology, 1979, 16, 445-450.	2.2	150

#	Article	IF	Citations
37	Complement C1q Is Dramatically Up-Regulated in Brain Microglia in Response to Transient Global Cerebral Ischemia. Journal of Immunology, 2000, 164, 5446-5452.	0.8	146
38	The Biological Functions of MBL-Associated Serine Proteases (MASPs). Immunobiology, 2002, 205, 467-475.	1.9	143
39	Interaction of 125 I-labelled complement subcomponents Cr and Cs with protease inhibitors in plasma. FEBS Letters, 1979, 97, 111-115.	2.8	142
40	Interaction of C1q receptor with lung surfactant protein A. European Journal of Immunology, 1992, 22, 1437-1445.	2.9	139
41	Mannan binding lectin and its interaction with immunoglobulins in health and in disease. Immunology Letters, 2006, 106, 103-110.	2.5	139
42	Differential substrate and inhibitor profiles for human MASP-1 and MASP-2. Molecular Immunology, 2004, 40, 921-929.	2.2	134
43	Complement factor I in health and disease. Molecular Immunology, 2011, 48, 1611-1620.	2.2	133
44	A recombinant trimeric surfactant protein D carbohydrate recognition domain inhibits respiratory syncytial virus infectionin vitro andin vivo. European Journal of Immunology, 1999, 29, 3478-3484.	2.9	132
45	Carbohydrate-independent recognition of collagens by the macrophage mannose receptor. European Journal of Immunology, 2006, 36, 1074-1082.	2.9	130
46	Binding of host collectins to the pathogenic yeast Cryptococcus neoformans: human surfactant protein D acts as an agglutinin for acapsular yeast cells. Infection and Immunity, 1995, 63, 3360-3366.	2.2	127
47	The Factor H Variant Associated with Age-related Macular Degeneration (His-384) and the Non-disease-associated Form Bind Differentially to C-reactive Protein, Fibromodulin, DNA, and Necrotic Cells. Journal of Biological Chemistry, 2007, 282, 10894-10900.	3.4	126
48	Activation of mannanâ€binding lectinâ€associated serine proteases leads to generation of a fibrin clot. Immunology, 2010, 129, 482-495.	4.4	125
49	The Complement System in Schizophrenia. Drug News and Perspectives, 2008, 21, 200.	1.5	123
50	Structural basis for complement factor I control and its disease-associated sequence polymorphisms. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 12839-12844.	7.1	118
51	Human Follicular Lymphoma Cells Contain Oligomannose Glycans in the Antigen-binding Site of the B-cell Receptor. Journal of Biological Chemistry, 2007, 282, 7405-7415.	3.4	117
52	The Classical Activation Pathway of the Human Complement System Is Specifically Inhibited by Calreticulin from Trypanosoma cruzi. Journal of Immunology, 2004, 172, 3042-3050.	0.8	115
53	Interactions between Neisseria meningitidis and the complement system. Trends in Microbiology, 2007, 15, 233-240.	7.7	114
54	Structural insight on the recognition of surface-bound opsonins by the integrin I domain of complement receptor 3. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 16426-16431.	7.1	113

#	Article	IF	Citations
55	The action of MBL-associated serine protease 1 (MASP1) on factor XIII and fibrinogen. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2008, 1784, 1294-1300.	2.3	107
56	Comparative study of the human ficolins reveals unique features of Ficolin-3 (Hakata antigen). Molecular Immunology, 2008, 45, 1623-1632.	2.2	106
57	A study of the structure of human complement component factor H by Fourier transform infrared spectroscopy and secondary structure averaging methods. Biochemistry, 1988, 27, 4004-4012.	2.5	104
58	Interferon gamma induces synthesis of complement alternative pathway proteins by human endothelial cells in culture.. Journal of Experimental Medicine, 1988, 168, 1917-1922.	8.5	101
59	The Glycosylation of Human Serum IgD and IgE and the Accessibility of Identified Oligomannose Structures for Interaction with Mannan-Binding Lectin. Journal of Immunology, 2004, 173, 6831-6840.	0.8	100
60	Binding of pulmonary surfactant proteins to carbon nanotubes; potential for damage to lung immune defense mechanisms. Carbon, 2007, 45, 607-617.	10.3	100
61	Pollen grains bind to lung alveolar type II cells (A549) via lung surfactant protein A (SP-A). Bioscience Reports, 1993, 13, 79-90.	2.4	99
62	Interaction of human monocytes, macrophages, and polymorphonuclear leukocytes with zymosan in vitro. Role of type 3 complement receptors and macrophage-derived complement.. Journal of Clinical Investigation, 1985, 76, 2368-2376.	8.2	99
63	Ligand binding by the pl50,95 antigen of U937 monocytic cells: properties in common with complement receptor type 3 (CR3). European Journal of Immunology, 1986, 16, 1117-1123.	2.9	98
64	Studies on the sensitivity to complementâ€mediated lysis of erythrocytes (Inab phenotype) with a deficiency of DAF (decay accelerating factor). British Journal of Haematology, 1989, 73, 248-253.	2.5	96
65	[1] Complement factor I and cofactors in control of complement system convertase enzymes. Methods in Enzymology, 1993, 223, 13-35.	1.0	95
66	A True Autoactivating Enzyme. Journal of Biological Chemistry, 2005, 280, 33435-33444.	3.4	92
67	Activity, disulphate mapping and structural modelling of the fifth domain of human Î²2 -glycoprotein I. FEBS Letters, 1992, 313, 193-197.	2.8	89
68	Understanding the laminated layer of larval Echinococcus II: immunology. Trends in Parasitology, 2011, 27, 264-273.	3.3	88
69	The C1q and collectin binding site within C1 q receptor (cell surface calreticulin). Immunopharmacology, 1997, 38, 73-80.	2.0	87
70	Interaction of C1q and the Collectins with the Potential Receptors Calreticulin (cClqR/Collectin) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 14	1.9	87
71	Serine proteases of the complement system. Biochemical Society Transactions, 2000, 28, 545-550.	3.4	85
72	C1: molecular interactions with activating systems. Trends in Immunology, 1991, 12, 307-311.	7.5	84

#	Article	IF	Citations
73	Pattern of degradation of human complement fragment, C3b. FEBS Letters, 1981, 132, 55-60.	2.8	83
74	Antibodies to Î²2 -glycoprotein I-a specific marker for the antiphospholipid syndrome. Clinical and Experimental Immunology, 1997, 109, 304-309.	2.6	83
75	Cellular confocal fluorescence studies and cytotoxic activity of new Zn(ii) bis(thiosemicarbazonato) complexes. Dalton Transactions, 2008, , 2107.	3.3	83
76	Role of early lectin pathway activation in the complement-mediated killing of Trypanosoma cruzi. Molecular Immunology, 2009, 47, 426-437.	2.2	82
77	Properdin and Factor H: Opposing Players on the Alternative Complement Pathway â€œSee-Sawâ€• Frontiers in Immunology, 2013, 4, 93.	4.8	80
78	Interactions between human complement components factor H, factor I and C3b. Biochemical Journal, 1997, 326, 553-561.	3.7	79
79	Complement-endothelial cell interactions: pathophysiological implications. Molecular Immunology, 1999, 36, 261-268.	2.2	78
80	Genetic influences on plasma CFH and CFHR1 concentrations and their role in susceptibility to age-related macular degeneration. Human Molecular Genetics, 2013, 22, 4857-4869.	2.9	77
81	A simplified procedure for the purification of C1Ì„-inactivator from human plasma Interaction with complement subcomponents C1Ì„r and C1Ì„s. FEBS Letters, 1977, 79, 45-50.	2.8	76
82	Kinetics of reaction of human C-inhibitor with the human complement system proteases Cr and Cs. Biochimica Et Biophysica Acta - Biomembranes, 1980, 612, 433-449.	2.6	76
83	Structural Model for the Mannose Receptor Family Uncovered by Electron Microscopy of Endo180 and the Mannose Receptor. Journal of Biological Chemistry, 2006, 281, 8780-8787.	3.4	76
84	Multiple routes of complement activation by Mycobacterium bovis BCG. Molecular Immunology, 2009, 46, 3367-3378.	2.2	73
85	Mutational Analyses of the Recombinant Globular Regions of Human C1q A, B, and C Chains Suggest an Essential Role for Arginine and Histidine Residues in the C1q-IgG Interaction. Journal of Immunology, 2004, 172, 4351-4358.	0.8	72
86	Molecular organization of human Ficolin-2. Molecular Immunology, 2007, 44, 401-411.	2.2	72
87	Early complement proteases: C1r, C1s and MASPs. A structural insight into activation and functions. Molecular Immunology, 2009, 46, 2745-2752.	2.2	72
88	Activities of the MBL-associated serine proteases (MASPs) and their regulation by natural inhibitors. Molecular Immunology, 1999, 36, 853-861.	2.2	71
89	The Secondary Structure of the von Willebrand Factor type A Domain in Factor B of Human Complement by Fourier Transform Infrared Spectroscopy. Journal of Molecular Biology, 1994, 238, 104-119.	4.2	70
90	Classical pathway complement activity in schizophrenia. Neuroscience Letters, 2005, 374, 35-37.	2.1	70

#	Article	IF	Citations
91	Recognition ofCandida albicansby Mannanâ€Binding Lectin In Vitro and In Vivo. Journal of Infectious Diseases, 2006, 193, 1589-1597.	4.0	67
92	High glucose disrupts oligosaccharide recognition function via competitive inhibition: A potential mechanism for immune dysregulation in diabetes mellitus. Immunobiology, 2011, 216, 126-131.	1.9	67
93	Oligomeric domain structure of human complement factor H by x-ray and neutron solution scattering. Biochemistry, 1991, 30, 2847-2857.	2.5	62
94	Biochemical studies on red blood cells from a patient with the Inab phenotype (decay-accelerating) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.4	62
95	Mannose-Binding Lectin Is a Disease Modifier in Clinical Malaria and May Function as Opsonin forPlasmodium falciparum- Infected Erythrocytes. Infection and Immunity, 2003, 71, 5245-5253.	2.2	62
96	Increased complement classical and mannan-binding lectin pathway activities in schizophrenia. Neuroscience Letters, 2006, 404, 336-341.	2.1	62
97	Mannan binding lectin and viral hepatitis. Immunology Letters, 2007, 108, 34-44.	2.5	62
98	Molecular modelling of human complement component C3 and its fragments by solution scattering. FEBS Journal, 1986, 157, 155-168.	0.2	61
99	Human Lung Surfactant Protein A Exists in Several Different Oligomeric States: Oligomer Size Distribution Varies between Patient Groups. Molecular Medicine, 1998, 4, 266-275.	4.4	61
100	Analogous Interactions in Initiating Complexes of the Classical and Lectin Pathways of Complement. Journal of Immunology, 2009, 182, 7708-7717.	0.8	59
101	Sequence polymorphism of human complement factor H. Immunogenetics, 1988, 27, 211-214.	2.4	57
102	Complement activation by carbon nanotubes and its influence on the phagocytosis and cytokine response by macrophages. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 1287-1299.	3.3	57
103	[5] Preparation and properties of human inhibitor. Methods in Enzymology, 1981, 80 Pt C, 43-54.	1.0	56
104	Complement activation by carbon nanotubes. Advanced Drug Delivery Reviews, 2011, 63, 1031-1041.	13.7	55
105	Recombinant surfactant protein-D selectively increases apoptosis in eosinophils of allergic asthmatics and enhances uptake of apoptotic eosinophils by macrophages. International Immunology, 2008, 20, 993-1007.	4.0	54
106	[4] The human complement system serine proteases and and their proenzymes. Methods in Enzymology, 1981, 80 Pt C, 26-42.	1.0	53
107	Genetics and Deficiencies of the Soluble Regulatory Proteins of the Complement System. International Reviews of Immunology, 1993, 10, 65-86.	3.3	53
108	Localisation of the C1q binding site within C 1 q receptor/calreticulin. FEBS Letters, 1996, 397, 245-249.	2.8	53

#	Article	IF	Citations
109	Interaction of C-inhibitor with the Cr and Cs subcomponents in human C. Biochimica Et Biophysica Acta (BBA) - Protein Structure, 1979, 576, 151-162.	1.7	52
110	Specific interaction of hepatitis C virus glycoproteins with mannan binding lectin inhibits virus entry. Protein and Cell, 2010, 1, 664-674.	11.0	52
111	Expression of complement factor H on the cell surface of the human monocytic cell line U937. European Journal of Immunology, 1985, 15, 935-941.	2.9	51
112	Biochemistry and genetics of mannan-binding lectin (MBL). Biochemical Society Transactions, 2003, 31, 748-752.	3.4	51
113	Molecular Interactions between MASP-2, C4, and C2 and Their Activation Fragments Leading to Complement Activation via the Lectin Pathway. Journal of Biological Chemistry, 2007, 282, 7844-7851.	3.4	51
114	Effects of Covalent Functionalization on the Biocompatibility Characteristics of Multi-Walled Carbon Nanotubes. Journal of Nanoscience and Nanotechnology, 2008, 8, 2347-2356.	0.9	51
115	Collectins and their role in lung immunity. Journal of Leukocyte Biology, 2004, 75, 27-33.	3.3	50
116	Lung Surfactant Protein A Provides a Route of Entry for Respiratory Syncytial Virus into Host Cells. Viral Immunology, 2000, 13, 125-135.	1.3	48
117	C1q binding and complement activation by prions and amyloids. Immunobiology, 2007, 212, 355-362.	1.9	48
118	Macrophage Scavenger Receptor A Mediates Adhesion to Apolipoproteins A-I and E. Biochemistry, 2009, 48, 11858-11871.	2.5	48
119	Identification of four novel DC-SIGN ligands on Mycobacterium bovis BCG. Protein and Cell, 2010, 1, 859-870.	11.0	48
120	Low-dose recombinant properdin provides substantial protection againstStreptococcus pneumoniaeandNeisseria meningitidisinfection. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 5301-5306.	7.1	48
121	Isolation of a human endothelial cell C1q receptor (C1qR). Journal of Leukocyte Biology, 1993, 53, 179-184.	3.3	47
122	Monoglucosylated glycans in the secreted human complement component C3: implications for protein biosynthesis and structure. FEBS Letters, 2004, 566, 270-274.	2.8	47
123	Complement activation by phospholipids: the interplay of factor H and C1q. Protein and Cell, 2010, 1, 1033-1049.	11.0	47
124	Characterization of xenopus laevis complement factor I structureâ€”conservation of modular structure except for an unusual insert not present in human factor I. Molecular Immunology, 1993, 30, 1249-1256.	2.2	46
125	How Echinococcus granulosus Deals with Complement. Parasitology Today, 2000, 16, 168-172.	3.0	46
126	Expression of the Proteinase Specialized in Bone Resorption, Cathepsin K, in Granulomatous Inflammation. Molecular Medicine, 2000, 6, 648-659.	4.4	46

#	Article	IF	Citations
127	Echinococcus granulosus: The establishment of the metacestode is associated with control of complement-mediated early inflammation. Experimental Parasitology, 2008, 118, 188-196.	1.2	46
128	Associative and Structural Properties of the Region of Complement Factor H Encompassing the Tyr402His Disease-related Polymorphism and its Interactions with Heparin. Journal of Molecular Biology, 2007, 368, 564-581.	4.2	44
129	Interaction of Mannan Binding Lectin with Î±2 Macroglobulin via Exposed Oligomannose Glycans. Journal of Biological Chemistry, 2006, 281, 6955-6963.	3.4	43
130	Lectin pathway effector enzyme mannanâ€binding lectinâ€associated serine proteaseâ€2 can activate native complement C3 in absence of C4 and/or C2. FASEB Journal, 2017, 31, 2210-2219.	0.5	43
131	Intramolecular general acid catalysis in the binding reactions of Î±2 and complement components C3 and C4. Bioscience Reports, 1981, 1, 461-468.	2.4	42
132	Immune attack on nanoparticles. Nature Nanotechnology, 2011, 6, 80-81.	31.5	42
133	In vitro biosynthesis of complement factor I by human endothelial cells. European Journal of Immunology, 1992, 22, 213-217.	2.9	41
134	Target Pattern Recognition by Complement Proteins of the Classical and Alternative Pathways. Advances in Experimental Medicine and Biology, 2009, 653, 117-128.	1.6	41
135	Collectins and innate immunity in the lung. Microbes and Infection, 2000, 2, 273-278.	1.9	40
136	Complement C4B protein in schizophrenia. World Journal of Biological Psychiatry, 2008, 9, 225-230.	2.6	40
137	Identification of human complement Factor H as a ligand for L-selectin. Biochemical Journal, 1999, 341, 61-69.	3.7	39
138	Recognition of acetylated oligosaccharides by human L-ficolin. Immunology Letters, 2008, 118, 152-156.	2.5	39
139	Length variation within intron 2 of the human IL-1 receptor antagonist protein gene (IL1RN). Nucleic Acids Research, 1991, 19, 5095-5095.	14.5	38
140	Human ?2-glycoprotein I: molecular analysis of DNA and amino acid polymorphism. Human Genetics, 1993, 91, 401-2.	3.8	38
141	Severe fibrosis in hepatitis C virus-infected patients is associated with increased activity of the mannan-binding lectin (MBL)/MBL-associated serine protease 1 (MASP-1) complex. Clinical and Experimental Immunology, 2006, 147, 061127015327009-???.	2.6	38
142	A monoclonal antibody against human complement component C3: the production of C3 by human cellsin vitro. European Journal of Immunology, 1981, 11, 140-146.	2.9	37
143	Ligands and receptors of lung surfactant proteins SP-A and SP-D. Frontiers in Bioscience - Landmark, 2013, 18, 1129.	3.0	37
144	Factor H as a regulator of the classical pathway activation. Immunobiology, 2012, 217, 162-168.	1.9	36

#	Article	IF	Citations
145	Complement factor H interferes with Mycobacterium bovis BCG entry into macrophages and modulates the pro-inflammatory cytokine response. Immunobiology, 2016, 221, 944-952.	1.9	36
146	Degradation of C1-Inhibitor by Plasmin: Implications for the Control of Inflammatory Processes. Molecular Medicine, 1997, 3, 385-396.	4.4	35
147	Human Complement Factor I Does Not Require Cofactors for Cleavage of Synthetic Substrates. Journal of Immunology, 2004, 173, 367-375.	0.8	35
148	ASchistosomaprotein, Sh-TOR, is a novel inhibitor of complement which binds human C2. FEBS Letters, 2000, 470, 131-134.	2.8	34
149	The Catalytically Active Serine Protease Domain of Human Complement Factor I. Biochemistry, 2005, 44, 6239-6249.	2.5	34
150	Prion protein activates and fixes complement directly via the classical pathway: Implications for the mechanism of scrapie agent propagation in lymphoid tissue. Molecular Immunology, 2007, 44, 2997-3004.	2.2	34
151	Human complement Factor H modulates C1q-mediated phagocytosis of apoptotic cells. Immunobiology, 2012, 217, 455-464.	1.9	34
152	Innate immune humoral factors, C1q and factor H, with differential pattern recognition properties, alter macrophage response to carbon nanotubes. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 2109-2118.	3.3	34
153	Human Properdin Opsonizes Nanoparticles and Triggers a Potent Pro-inflammatory Response by Macrophages without Involving Complement Activation. Frontiers in Immunology, 2018, 9, 131.	4.8	34
154	Investigation of the mechanisms of anti-complement activity in Ixodes ricinus ticks. Molecular Immunology, 2005, 42, 31-38.	2.2	33
155	Isolation and Comparison of the Proenzyme and Activated Forms of the Human Serum Complement Subcomponents C1r and C1s. Biochemical Society Transactions, 1976, 4, 127-129.	3.4	32
156	AUTOLYTIC FRAGMENTATION OF COMPLEMENT COMPONENTS C3 AND C4 AND ITS RELATIONSHIP TO COVALENT BINDING ACTIVITY. Annals of the New York Academy of Sciences, 1983, 421, 259-276.	3.8	32
157	Interactions of carbohydrates and lectins with complement. Biochemical Society Transactions, 1994, 22, 106-111.	3.4	32
158	myo-Inositol hexakisphosphate is a major component of an extracellular structure in the parasitic cestode Echinococcus granulosus. Biochemical Journal, 2002, 362, 297-304.	3.7	32
159	Scrapie Pathogenesis: The Role of Complement C1q in Scrapie Agent Uptake by Conventional Dendritic Cells. Journal of Immunology, 2009, 182, 1305-1313.	0.8	32
160	Partial characterization of human complement factor H by protein and cDNA sequencing: Homology with other complement and non-complement proteins. Bioscience Reports, 1986, 6, 65-72.	2.4	31
161	Mannan-binding lectin in human serum, cerebrospinal fluid and brain tissue and its role in AlzheimerÊ¼s disease. NeuroReport, 1998, 9, 1491-1495.	1.2	31
162	â€˜Greenâ€™ derivatization of carbon nanotubes with Nylon 6 andl-alanine. Journal of Materials Chemistry, 2006, 16, 4420-4426.	6.7	31

#	Article	IF	Citations
163	The human lung surfactant proteins A (SP-A) and D (SP-D) interact with apoptotic target cells by different binding mechanisms. Immunobiology, 2010, 215, 551-558.	1.9	31
164	Interaction of C1q, and other proteins containing collagen-like domains, with the C1q receptor. Biochemical Society Transactions, 1990, 18, 1145-1148.	3.4	30
165	Unique precipitation and exocytosis of a calcium salt ofmyo-inositol hexakisphosphate in larvalEchinococcus granulosus. Journal of Cellular Biochemistry, 2004, 93, 1272-1281.	2.6	30
166	Collectins, collectin receptors and the lectin pathway of complement activation. Clinical and Experimental Immunology, 2008, 97, 4-9.	2.6	30
167	Interactions of complement proteins C1q and factor H with lipid A and Escherichia coli: further evidence that factor H regulates the classical complement pathway. Protein and Cell, 2011, 2, 320-332.	11.0	30
168	Molecular modeling of human complement component C4 and its fragments by x-ray and neutron solution scattering. Biochemistry, 1990, 29, 1167-1175.	2.5	29
169	Complement C1qâ€target proteins recognition is inhibited by electric moment effectors. Journal of Molecular Recognition, 2007, 20, 405-415.	2.1	29
170	A recombinant two-module form of human properdin is an inhibitor of the complement alternative pathway. Molecular Immunology, 2016, 73, 76-87.	2.2	29
171	Complement C4bC2 complex formation: an investigation by surface plasmon resonance. BBA - Proteins and Proteomics, 2001, 1544, 96-112.	2.1	28
172	Evaluation and clinical interest of mannan binding lectin function in human plasma. Molecular Immunology, 2002, 39, 465-473.	2.2	27
173	Heterogeneity of MBLâ€“MASP complexes. Molecular Immunology, 2006, 43, 1286-1292.	2.2	27
174	Human complement factor I glycosylation: Structural and functional characterisation of the N-linked oligosaccharides. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2006, 1764, 1757-1766.	2.3	27
175	Complement research in the 18thâ€“21st centuries: Progress comes with new technology. Immunobiology, 2016, 221, 1037-1045.	1.9	27
176	Assignment of apolipoprotein H (APOH: beta-2-glycoprotein I) to human chromosome 17q23â†'qter; determination of the major expression site. Cytogenetic and Genome Research, 1992, 60, 31-33.	1.1	26
177	Collectins and viral infection. Trends in Microbiology, 1995, 3, 240-244.	7.7	26
178	Induction of TNF-Î± release from human buffy coat cells byPseudomonas aeruginosais reduced by lung surfactant protein A. FEBS Letters, 1998, 437, 65-69.	2.8	26
179	Structure and specificity of complement receptors. Immunology Letters, 1987, 14, 183-190.	2.5	25
180	Human Interleukin-1 receptor antagonist High yield expression in E. coli and examination of cysteine residues. FEBS Letters, 1992, 310, 63-65.	2.8	25

#	Article	IF	Citations
181	Control of host complement activation by the Echinococcus granulosus hydatid cyst. Immunopharmacology, 1999, 42, 91-98.	2.0	24
182	Contribution of C5-mediated mechanisms to host defence against Echinococcus granulosus hydatid infection. Parasite Immunology, 2000, 22, 445-453.	1.5	23
183	myo-Inositol hexakisphosphate is a major component of an extracellular structure in the parasitic cestode Echinococcus granulosus. Biochemical Journal, 2002, 362, 297.	3.7	22
184	Cryoglobulins as indicators of upregulated immune response in schizophrenia. Clinical Biochemistry, 2008, 41, 355-360.	1.9	22
185	Potential influences of complement factor H in autoimmune inflammatory and thrombotic disorders. Molecular Immunology, 2017, 84, 84-106.	2.2	22
186	Dye-ligand affinity purification of human complement factor B and Î²2 glycoprotein I. Journal of Immunological Methods, 1993, 157, 25-30.	1.4	21
187	Production and functional activity of a recombinant von Willebrand factor-A domain from human complement factor B. Biochemical Journal, 1999, 342, 625-632.	3.7	21
188	Effect of Functionalization of Carbon Nanotubes with Psychosine on Complement Activation and Protein Adsorption. Journal of Biomedical Nanotechnology, 2011, 7, 830-839.	1.1	21
189	A potential anti-coagulant role of complement factor H. Molecular Immunology, 2014, 59, 188-193.	2.2	21
190	[2] The first component of human complementâ€”C1. Methods in Enzymology, 1981, 80 Pt C, 6-16.	1.0	20
191	Identification of human complement Factor H as a ligand for L-selectin. Biochemical Journal, 1999, 341, 61.	3.7	20
192	Human L-ficolin, a Recognition Molecule of the Lectin Activation Pathway of Complement, Activates Complement by Binding to Pneumolysin, the Major Toxin of Streptococcus pneumoniae. PLoS ONE, 2013, 8, e82583.	2.5	20
193	C4b Binding Protein Acts as an Innate Immune Effector Against Influenza A Virus. Frontiers in Immunology, 2020, 11, 585361.	4.8	20
194	Appearance of acceptor-bound C3b on HLA-DR positive macrophages and on stimulated U937 cells; Inhibition of FcÎ³-receptors by the covalently fixed C3 fragments. Molecular Immunology, 1988, 25, 295-303.	2.2	19
195	Echinococcus granulosus:An Intraperitoneal Diffusion Chamber Model of Secondary Infection in Mice. Experimental Parasitology, 1998, 90, 270-276.	1.2	19
196	Mechanism of Action of Anti-C1-Inhibitor Autoantibodies: Prevention of the Formation of Stable C1s-C1-inh Complexes. Molecular Medicine, 1998, 4, 119-128.	4.4	19
197	Prediction from sequence comparisons of residues of factor H involved in the interaction with complement component C3b. Biochemical Journal, 1996, 315, 523-531.	3.7	18
198	Discrete MBL-MASP Complexes Show Wide Inter-Individual Variability in Concentration: Data from UK vs Armenian Populations. International Journal of Immunopathology and Pharmacology, 2006, 19, 567-580.	2.1	18

#	Article	IF	Citations
199	The complement system of the goat: Haemolytic assays and isolation of major proteins. BMC Veterinary Research, 2012, 8, 91.	1.9	18
200	Hydrodynamic Parameters of the Detergent-Solubilised Hydrogenase from Paracoccus denitrificans. FEBS Journal, 1979, 97, 119-126.	0.2	17
201	Role of complement receptor CR1 in the breakdown of soluble and zymosan-bound C3b. Biochemical Society Transactions, 1984, 12, 781-782.	3.4	17
202	Comparison of complement activation in vitro by different Echinococcus granulosus extracts. Parasite Immunology, 1996, 18, 371-375.	1.5	17
203	Characterization of Radioiodinated Lung Surfactant Protein a (SP-A) and the Effects of Oxidation on SP-A Quaternary Structure and Activity. Experimental Lung Research, 1996, 22, 467-487.	1.2	17
204	Human Immunoglobulin Glycosylation and the Lectin Pathway of Complement Activation. Advances in Experimental Medicine and Biology, 2005, 564, 27-43.	1.6	17
205	Surface-bound myeloperoxidase is a ligand for recognition of late apoptotic neutrophils by human lung surfactant proteins A and D. Protein and Cell, 2010, 1, 563-572.	11.0	17
206	Pulmonary surfactant protein SP-D opsonises carbon nanotubes and augments their phagocytosis and subsequent pro-inflammatory immune response. Nanoscale, 2017, 9, 1097-1109.	5.6	17
207	Human complement factor I: its expression by insect cells and its biochemical and structural characterisation. Molecular Immunology, 1998, 35, 503-512.	2.2	16
208	Host-derived annexin II at the hostâ€“parasite interface of the Echinococcus granulosus hydatid cyst. Molecular and Biochemical Parasitology, 2000, 110, 171-176.	1.1	16
209	Evolution of innate immune systems. Biochemistry and Molecular Biology Education, 2005, 33, 177-183.	1.2	16
210	Complement factor H in its alternative identity as adrenomedullin-binding protein 1. Molecular Immunology, 2015, 68, 45-48.	2.2	16
211	Î²-Sheet secondary structure of an LDL receptor domain from complement factor I by consensus structure predictions and spectroscopy. FEBS Letters, 1995, 371, 199-203.	2.8	15
212	Resistance of the Echinococcus granulosus cyst wall to complement activation: analysis of the role of InsP6deposits. Parasite Immunology, 2008, 30, 354-364.	1.5	15
213	Improvement of the expression and purification of Mycobacterium tuberculosis arylamine N-acetyltransferase (TBNAT) a potential target for novel anti-tubercular agents. Protein Expression and Purification, 2011, 80, 246-252.	1.3	15
214	Complement Deposition on Nanoparticles Can Modulate Immune Responses by Macrophage, B and T Cells. Journal of Biomedical Nanotechnology, 2016, 12, 197-216.	1.1	15
215	Human Properdin Modulates Macrophage: Mycobacterium bovis BCG Interaction via Thrombospondin Repeats 4 and 5. Frontiers in Immunology, 2018, 9, 533.	4.8	15
216	Studies on the isolation of human C1q-receptor. Biochemical Society Transactions, 1988, 16, 735-736.	3.4	14

#	Article	IF	Citations
217	Expression, purification, cocrystallization and preliminary crystallographic analysis of sucrose octasulfate/human complement regulator factor H SCRs 6â€“8. Acta Crystallographica Section F: Structural Biology Communications, 2007, 63, 480-483.	0.7	14
218	mRNA coding for a truncated form of human complement factor H. Biochemical Society Transactions, 1987, 15, 651-652.	3.4	13
219	Human interleukin-1 receptor antagonist is expressed in liver. FEBS Letters, 1992, 310, 60-62.	2.8	13
220	A secondary C1s interaction site on C1-inhibitor is essential for formation of a stable enzyme-inhibitor complex. FEBS Letters, 1997, 405, 42-46.	2.8	13
221	Interactions of the innate immune system with carbon nanotubes. Nanoscale Horizons, 2017, 2, 174-186.	8.0	13
222	Serine proteases of the complement lectin pathway and their genetic variations in ischaemic stroke. Journal of Clinical Pathology, 2018, 71, 141-147.	2.0	13
223	Substances that can trigger activation of the alternative pathway of complement have anti-melanoma activity in mice. International Journal of Cancer, 1984, 33, 683-687.	5.1	12
224	Inhibitory effect of Zn2+ ions on the degradation of the complement activation fragment C3b. Biochemical Society Transactions, 1986, 14, 73-74.	3.4	12
225	Immunoblotting analysis of the peptide chain structure of the physiological breakdown products of the third component of human complement. Electrophoresis, 1986, 7, 379-386.	2.4	12
226	Complement-Independent Modulation of Influenza A Virus Infection by Factor H. Frontiers in Immunology, 2020, 11, 355.	4.8	12
227	Complement Proteins as Soluble Pattern Recognition Receptors for Pathogenic Viruses. Viruses, 2021, 13, 824.	3.3	12
228	Identification of high-mannose and multiantennary complex-type N-linked glycans containing Î±-galactose epitopes from Nurse shark IgM heavy chain. Glycoconjugate Journal, 2009, 26, 1055-1064.	2.7	11
229	Human Properdin Released By Infiltrating Neutrophils Can Modulate Influenza A Virus Infection. Frontiers in Immunology, 2021, 12, 747654.	4.8	11
230	An angle-variable three-dimensional pulsed field gel electrophoresis system. Analytical Biochemistry, 1991, 192, 32-38.	2.4	10
231	Binding sites involved in the formation of the C3(H2O)-factor B complex of the alternative pathway of complement. Biochemical Society Transactions, 1994, 22, 2S-2S.	3.4	10
232	Echinococcus granulosus antigen 5 may be a serine proteinase. Parasite Immunology, 1997, 19, 385-385.	1.5	10
233	The Effect of Danazol on the Production of C1 Inhibitor in the Guinea Pig. Complement (Basel,) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.9	9
234	Secretion of functionally active complement factor H related protein 5 (FHR5) by primary tumour cells derived from Glioblastoma Multiforme patients. Immunobiology, 2019, 224, 625-631.	1.9	9

#	Article	IF	Citations
235	A recombinant trimeric surfactant protein D carbohydrate recognition domain inhibits respiratory syncytial virus infection in vitro and in vivo. European Journal of Immunology, 1999, 29, 3478-3484.	2.9	9
236	The generation of active fragments of complement receptor type 2 by trypsin digestion. FEBS Letters, 1985, 189, 195-201.	2.8	8
237	Role of the distal hinge region of C1-inhibitor in the regulation of C1s activity. FEBS Letters, 1997, 412, 506-510.	2.8	8
238	Complement-endothelial cell interactions: pathophysiological implications. Molecular Immunology, 2000, 37, 91.	2.2	8
239	In vivo pharmacokinetics of calreticulin S-domain, an inhibitor of the classical complement pathway. International Immunopharmacology, 2002, 2, 415-422.	3.8	8
240	Enterococcus faecalis Escapes Complement-Mediated Killing via Recruitment of Complement Factor H. Journal of Infectious Diseases, 2019, 220, 1061-1070.	4.0	8
241	Application of the immunoblotting technique to the study of single protein species in complex biological fluids: A model study with alpha-2-macroglobulin. Electrophoresis, 1985, 6, 227-234.	2.4	7
242	Sequence analysis of a cDNA clone encoding the C-terminal end of human complement factor H. Bioscience Reports, 1987, 7, 201-207.	2.4	7
243	Comparison of the complement system protein complexes formed by C1q and MBL. Biochemical Society Transactions, 1997, 25, 41S-41S.	3.4	7
244	Assessment of in vivo complement activation on the Echinococcus granulosus hydatid cyst wall. Parasite Immunology, 2001, 23, 655-658.	1.5	7
245	Recognition of Carbon Nanotubes by the Human Innate Immune System. Carbon Nanostructures, 2011, , 183-210.	0.1	7
246	Complement Activation. Frontiers in Nanobiomedical Research, 2013, , 357-384.	0.1	7
247	Recombinant chemotaxis inhibitory protein of Staphylococcus aureus (CHIPS) protects against LPS-induced lung injury in mice. Clinical Immunology, 2018, 197, 27-33.	3.2	7
248	Complement Dependent and Independent Interaction Between Bovine Conglutinin and Mycobacterium bovis BCG: Implications in Bovine Tuberculosis. Frontiers in Immunology, 2019, 9, 3159.	4.8	7
249	Production and functional activity of a recombinant von Willebrand factor-A domain from human complement factor B. Biochemical Journal, 1999, 342, 625.	3.7	7
250	Lack of abnormal sensitivity to complement-mediated lysis in erythrocytes deficient only in decay accelerating factor. Biochemical Society Transactions, 1989, 17, 514-514.	3.4	6
251	An investigation of the interaction between human complement factor H and C3b. Biochemical Society Transactions, 1995, 23, 53S-53S.	3.4	6
252	Crystal structure of VC1805, a conserved hypothetical protein from a Vibrio cholerae pathogenicity island, reveals homology to human p32. Proteins: Structure, Function and Bioinformatics, 2008, 71, 1563-1571.	2.6	6

#	Article	IF	Citations
253	Structures of the rat complement regulator CrrY. Acta Crystallographica Section F: Structural Biology Communications, 2011, 67, 739-743.	0.7	6
254	Chromosomal mapping of the human interleukin-1 receptor antagonist gene (IL-1RN) and isolation of specific YAC clones. Agents and Actions, 1993, 38, C59-C60.	0.7	5
255	Similarities between complement factor H and Î²2 glycoprotein 1: Phospholipid binding and autoantibodies. Molecular Immunology, 1998, 35, 375.	2.2	5
256	Enzyme-independent, orientation-selective conjugation of whole human complement C3 to protein surfaces. Journal of Immunological Methods, 2008, 337, 49-54.	1.4	5
257	A Chemical Approach to Immunoprotein Engineering: Chemoselective Functionalization of Thioester Proteins in Their Native State. ChemBioChem, 2009, 10, 1340-1343.	2.6	5
258	Chemical labelling of active serum thioester proteins for quantification. Immunobiology, 2012, 217, 256-264.	1.9	5
259	Purification, Quantification, and Functional Analysis of Complement Factor H. Methods in Molecular Biology, 2014, 1100, 207-223.	0.9	5
260	Interactions in the complement-mediated lysis of blood group AB erythrocytes sensitized simultaneously with anti-A and anti-B monoclonal antibodies. Immunology Letters, 1993, 35, 219-228.	2.5	4
261	Chapter 6. Complement Control Proteins and Receptors: From FH to CR4. , 2008, , 84-104.		4
262	Monoclonal antibodies against complement component C3. Biochemical Society Transactions, 1987, 15, 653-654.	3.4	3
263	An indirect effect of an antibody on complement deposition and lysis of differently sensitized surrounding cells. Molecular Immunology, 1994, 31, 901-911.	2.2	3
264	Mapping the bovine factor H gene to Chromosome 16 by SSCP analysis. Mammalian Genome, 1997, 8, 77-78.	2.2	3
265	Cathepsin K expression in epithelioid and multinucleated giant cells. Journal of Pathology, 2002, 197, 690-690.	4.5	3
266	Immunochemical Composition of Cryoglobulins Generated in Stroke. Journal of Clinical Immunology, 2009, 29, 274-281.	3.8	3
267	Towards the crystal structure of intact Human Complement Factor I. Molecular Immunology, 2009, 46, 2864-2865.	2.2	3
268	European Union funded project on the development of a whole complement deficiency screening ELISAâ€"A story of success and an exceptional manager: Mohamed R. Daha. Molecular Immunology, 2015, 68, 63-66.	2.2	3
269	Localisation of a group of antigenic sites in complement component C3, and identification of a new fragmentation pattern. BBA - Proteins and Proteomics, 1984, 789, 119-127.	2.1	2
270	Complement, Classical Pathway. , 1998, , 604-612.		2

#	Article	IF	Citations
271	Acid-Treated Multi-Walled Carbon Nanotubes Coated with Lung Surfactant Protein SP-A Do Not Induce a Lung Inflammatory Response. Journal of Advanced Microscopy Research, 2013, 8, 93-99.	0.3	2
272	Intrinsic Chemical Reactivity of Activated Human Complement Component C3. Immunobiology, 2022, , 152209.	1.9	2
273	C2 by-pass: Cross-talk between the complement classical and alternative pathways. Immunobiology, 2022, 227, 152225.	1.9	2
274	The Covalent Interactions of Complement Components and Other Proteins with Antibodies and Cell Surfaces. , 1981, 2, 224-230.		1
275	Towards a structural basis for complement factor H linked age-related macular degeneration. Molecular Immunology, 2007, 44, 3930-3931.	2.2	1
276	Evidence for a monomer-dimer equilibrium in native human Factor H. Molecular Immunology, 2007, 44, 3986.	2.2	1
277	Abnormal immune complexes in schizophrenia. Neurochemical Journal, 2008, 2, 329-330.	0.5	1
278	Complement Factor I. , 2013, , 2875-2880.		1
279	Complement Activation. Frontiers in Nanobiomedical Research, 2016, , 303-330.	0.1	1
280	Mannose-Binding Lectin in Human Health and Disease. , 2021, , 17-47.		1
281	Interaction of the Immune System with Nanoparticles. , 2015, , 1-8.		1
282	WM1 monoclonal antibody inhibits the binding of activated C3 to surfaces. Molecular Immunology, 1982, 19, 1402.	2.2	0
283	Human complement factor H is an L-selectin ligand. Molecular Immunology, 1998, 35, 376.	2.2	0
284	Activity and regulation of human MBL associated serine protease1(MASP-1). Biochemical Society Transactions, 2001, 29, A129-A129.	3.4	0
285	Characterization of complement protein C1q binding to U937 myelomonocytic cells. Biochemical Society Transactions, 2002, 30, A118-A118.	3.4	0
286	Ficolin isolation from human serum. Biochemical Society Transactions, 2002, 30, A118-A118.	3.4	0
287	Activity studies on human complement factor I (FI). Biochemical Society Transactions, 2002, 30, A118-A118.	3.4	0
288	A molecular model for human factor B by constrained scattering modelling. Biochemical Society Transactions, 2002, 30, A119-A119.	3.4	0

#	Article	IF	Citations
289	Mannan-binding lectin associated serine protease 2 (MASP-2) activates prothrombin directly and initiates low-level clotting. Molecular Immunology, 2007, 44, 198.	2.2	0
290	Crystallographic studies of human complement factor I. Molecular Immunology, 2007, 44, 233-234.	2.2	0
291	Investigation of L-ficolin binding specificity. Molecular Immunology, 2007, 44, 3959.	2.2	0
292	Interactions between factor H and Neisseria meningitidis. Molecular Immunology, 2007, 44, 3980.	2.2	0
293	879 ROLE OF SOLUBLE LECTIN L-FICOLIN IMMUNE RECOGNITION IN HEPATITIS C VIRUS INFECTION. Journal of Hepatology, 2009, 50, S320.	3.7	0
294	The Roles and Contributions of the Complement System in the Pathophysiology of Autoimmune Diseases. , 2014, , 217-227.		0
295	The Roles and Contributions of the Complement System in the Pathophysiology of Autoimmune Diseases. , 2020, , 263-273.		0
296	SP-A. , 2000, , 41-45.		0
297	Molecular Biology of the Human Complement Class III Products of the MHC: Factor I and Its Cofactors. , 1986, , 299-313.		0
298	Interaction of the Immune System with Nanoparticles. , 2016, , 1678-1685.		0